Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD)

Table 1 Demographic and main clinical characteristics of the study groups

Characteristics	CTR (n = 48)	MCI-AD (n = 94)	AMY+ MCI (n = 39)
Age, years	69.0 ± 9.7	75.3 ± 5.7	74.2 ± 6.4
Sex
Male	12	42	21
Female	36	52	18
Education, years	10.0 ± 4.0	10.1 ± 2.0	10.5 ± 4.1
ApoE ε4 allele status^a	N/A	N/A	14/22^b
Baseline NPS
MMSE	29.0 ± 0.9	26.0 ± 1.1	27.1 ± 2.6
Follow-up duration, years	–	3.2 ± 1.5	2.3 ± 1.0
Conversion time, months	–	23.2 ± 16.2 (range 6–98)	–
Follow-up MMSE score	–	22.3 ± 2.0	25.9 ± 3.4
ΔMMSE/year		− 1.5 ± 1.2	− 0.6 ± 0.4

Abbreviations: AMY+ MCI Patients with mild cognitive impairment who had a positive result for a brain amyloidosis biomarker, ApoE Apolipoprotein E, CTR Healthy volunteer control subjects, MCI-AD Patients with mild cognitive impairment due to Alzheimer’s disease, MMSE Mini Mental State Examination, ΔMMSE Reduction in Mini Mental State Examination score, NPS Neuropsychology
Data are presented as mean ± SD
^aEither as homozygous or heterozygous for ApoE ε4 allele
^bAvailable in 22 of 39 patients (3 of 22 homozygous and 11 of 22 heterozygous for ApoE ε4 allele) to date

ISSN: 1758-9193